Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Compatibility

Hygiene Clinical Trial

Official title:

Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00785655
• Other study ID #: LACAC_L_04299
• Status: Completed
• Phase: Phase 3
• First received: November 4, 2008
• Last updated: August 21, 2009
• Start date: July 2008
• Est. completion date: September 2008

Study information

• Verified date: August 2009
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Brazil: National Health Surveillance Agency
• Study type: Interventional

Clinical Trial Summary

To demonstrate the absence of irritation potential (primary dermical irritability and cumulated dermical irritability) and allergy (sensibilization) of the product Dermacyd PHDETINLYN Sweet Flower.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: September 2008
• Est. primary completion date: September 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 60 Years

Eligibility

Inclusion criteria:

• Phototype Skin I,II, III e IV

• Integral skin test in the region;

• Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion;

Exclusion criteria:

• Lactation or gestation

• Use of Antiinflammatory and/or immunossupression drugs

• Personnel history of atopy

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• History of sensitivity or irritation for topic products;

• Active cutaneous disease;

• Use of new drugs or cosmetics during the study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Hygiene

Intervention

Drug:
• Dermacyd PH_DETINLYN (Lactic Acid)

Locations

Country	Name	City	State
Brazil	Sanofi-Aventis Administrative Office	Sao Paulo

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The absence of primary and accumulated dermical irritability and dermical sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.		Throughout the study	No